Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis
NCT ID: NCT00303381
Last Updated: 2013-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
194 participants
INTERVENTIONAL
2001-12-31
2003-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Interferon-beta-1a, 44 microgram
Interferon-beta-1a, 44 microgram
Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
Interferon-beta-1a, 66 microgram
Interferon-beta-1a, 66 microgram
Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
Placebo
Placebo
Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interferon-beta-1a, 44 microgram
Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
Placebo
Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
Interferon-beta-1a, 66 microgram
Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of UC documented by clinical, radiological and endoscopic or histological findings
* Proctosigmoidoscopic diagnosis: at least left-sided disease; the extent of the colonic inflammation is to be more than 20 centimeter from the anal verge
* A flare in disease activity considered moderate in according to the UCSS during the 14 days before initiation of study medication. Moderate disease is defined as a UCSS between 6 and 10 with a UCSS Physician's Global Assessment less than (\<) 3 and a proctosigmoidoscopy score of 2 or 3
* At least one previous flare-up of UC
* Maintenance treatment with 5-aminosalicylic acid (5-ASA) at a stable dose for the management of UC is allowed, but not required. The daily dose of 5-ASA has to be stable for at least 4 weeks before Study Day 1 and has to be no more than 3.6 gram/day. This dose has to be maintained throughout the study. Corticosteroids will not be allowed during the study, with the exceptions of inhaled steroids and topical dermatological steroids
* Age ≥18 years, of either sex
* Adequate bone marrow reserve: white blood cells (WBC) greater than (\>) 3.5\*10\^9 per liter (/L), neutrophils \>1.5\*10 \^9 /L, thrombocytes \>100 \*10\^9 /L, hemoglobin \>8.5 gram per deciliter (g/dL)
* Female subjects are to be neither pregnant nor breast-feeding and has to lack childbearing potential, as will be defined by either being post-menopausal or surgically sterile or using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide or not pregnant which will be established by a negative serum or urinary Human chorionic gonadotrophin (hCG) test within 7 days before Study Day 1. A pregnancy test is not required if the subject was post-menopausal or surgically sterile
* Willingness and ability to comply with the protocol for the duration of the study
* Written informed consent, obtained before any study-related procedure not part of the subject's normal medical care, with the understanding that the subject can withdraw consent at any time without prejudice to his or her future medical care
Exclusion Criteria
* Any other investigational drug or any experimental procedure in the 4 weeks before Study Day 1
* More than three doses of rectally administered 5-ASA derivatives in the 2 weeks before Study Day 1
* More than two doses of systemically or rectally administered corticosteroids in the 14 days before Study Day 1
* Use of non-steroidal anti-inflammatory drugs (NSAIDs) or antibiotic therapy (e.g. metronidazole) in the 2 weeks before Study Day 1
* Use of codeine, other narcotics, loperamide or opiates after the Screening visit or during the study
* Stool examination positive for enteric pathogens, pathogenic ova, parasites, or Clostridium toxin at Screening
* Need for emergency surgery (uncontrollable hemorrhage, persistent non-inflammatory intestinal obstruction - at the Investigator's discretion - or perforation), elective surgery during the study, or surgery in the 4 weeks before study entry
* Inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase level \>2 times the upper limit of the normal range
* Inadequate renal function, defined by serum creatinine \>2.0 milligram per deciliter (mg/dL)
* Histopathological findings of high-grade dysplasia or history of cancer (except carcinoma in situ of the cervix or adequately treated basal cell or squamous cell carcinoma of the skin)
* Known allergies to paracetamol or to any of the ingredients of the medicinal product (that is, the active substance, human serum albumin or mannitol)
* Severe depressive disorder or suicidal ideation, or epilepsy with a history of seizures not adequately controlled by treatment
* Known alcohol or drug abuse within the past 5 years
* Other serious concurrent systemic disorders incompatible with the study (at the Investigator's discretion)
* Severe active infection (at the Investigator's discretion)
* Dependence on a liquid diet
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Serono International SA
INDUSTRY
EMD Serono
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claudia Pena Rossi, M.D.
Role: STUDY_DIRECTOR
Merck Serono International SA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Munich, , Germany
Research Site
Ness Ziona, , Israel
Research Site
The Hague, , Netherlands
Research Site
Singapore, , Singapore
Research Site
Solna, , Sweden
Research Site
Zug, , Switzerland
Research Site
Feltham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pena-Rossi C, Schreiber S, Golubovic G, Mertz-Nielsen A, Panes J, Rachmilewitz D, Shieh MJ, Simanenkov VI, Stanton D, Graffner H. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. Aliment Pharmacol Ther. 2008 Sep 15;28(6):758-67. doi: 10.1111/j.1365-2036.2008.03778.x.
Related Links
Access external resources that provide additional context or updates about the study.
Full FDA approved prescribing information can be found here
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22648
Identifier Type: -
Identifier Source: org_study_id